Get the Stockscreener App
1.96
2.08%
0.04
After Hours:
1.97
0.01
+0.51%
Engene Therapeutics Inc stock is traded at $1.96, with a volume of 1.98M.
It is up +2.08% in the last 24 hours and up +4.81% over the past month.
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
See More
Previous Close:
$1.92
Open:
$1.94
24h Volume:
1.98M
Relative Volume:
2.35
Market Cap:
$131.35M
Revenue:
-
Net Income/Loss:
$-122.44M
P/E Ratio:
-0.8696
EPS:
-2.254
Net Cash Flow:
$-103.79M
1W Performance:
+2.62%
1M Performance:
+4.81%
6M Performance:
-72.28%
1Y Performance:
-69.85%
1-Day Range:
$1.875
$1.9691
1-Week Range:
$1.875
$2.08
52-Week Range:
$1.40
$12.25
Engene Therapeutics Inc Stock (ENGN) Company Profile
Name
Engene Therapeutics Inc
Sector
Industry
Phone
(514) 332-4888
Address
4868 RUE LEVY, SUITE 220, SAINT-LAURENT
Compare ENGN vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENGN
Engene Therapeutics Inc
|
1.96 | 131.35M | 0 | -122.44M | -103.79M | -2.254 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Engene Therapeutics Inc Stock (ENGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | WBB Securities | Buy |
| Jan-30-26 | Initiated | Jefferies | Buy |
| Nov-11-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-18-25 | Initiated | Piper Sandler | Overweight |
| Feb-14-25 | Downgrade | UBS | Buy → Neutral |
| Dec-23-24 | Initiated | H.C. Wainwright | Buy |
| Nov-27-24 | Initiated | Raymond James | Outperform |
| Nov-18-24 | Initiated | JMP Securities | Mkt Outperform |
| Aug-28-24 | Initiated | Oppenheimer | Outperform |
| Apr-22-24 | Initiated | Wells Fargo | Overweight |
| Apr-15-24 | Initiated | Guggenheim | Buy |
| Mar-28-24 | Initiated | UBS | Buy |
| Mar-08-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | Leerink Partners | Outperform |
View All
Engene Therapeutics Inc Stock (ENGN) Latest News
Form 4 enGene Therapeutics Inc. For: 25 September By Investing.com - Investing.com Canada
At $1.97 a share, enGene Therapeutics (ENGN) interim medical chief bought 5,102 shares. - stocktitan.net
EnGene Therapeutics Inc.(NasdaqCM: ENGN) dropped from S&P Global BMI Index - marketscreener.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Definium Therapeutics (DFTX) and enGene Holdings (ENGN) - The Globe and Mail
UBS Maintains EnGene Therapeutics(ENGN.US) With Hold Rating, Maintains Target Price $2 - Moomoo
Transcript : EnGene Therapeutics Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-14-2026 07 - marketscreener.com
enGene Therapeutics: Slashing Cash Burn To Bring Their Asset To The Market - Seeking Alpha
enGene Therapeutics trades below cash value des... - Pluang
Analysts Are Bullish on These Healthcare Stocks: enGene Holdings (ENGN), Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
EnGene Therapeutics Posts $32.501M Net Loss and $0.47 EPS for Q3 2026 (NASDAQ: ENGN) - Kalkine Media
enGene Therapeutics Inc. reports results for the quarter ended July 31Earnings Summary - TradingView
Engene Holdings stock rating maintained at Market Perform by Citizens - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - cnn.com
enGene at Wells Fargo conference: bladder cancer push gains focus By Investing.com - Investing.com Canada
ENGN: Detalimogene voraplasmid nears pivotal data and FDA filing, targeting broad NMIBC adoption - TradingView
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update - BioSpace
enGene advances detalimogene bladder cancer therapy filing - grafa.com
enGene Reports $266.3M Cash, Reaffirms Q4 BLA Submission for detalimogene - Minichart
enGene Therapeutics Inc. 3Q FY2026: Net loss $32.5M, EPS ($0.47) — 10-Q Summary - TradingView
enGene Reports Q3 2026: $266.3M Cash, $32.5M Net Loss; BLA Filing Planned 4Q26 - TradingView
Gene-therapy firm enGene (ENGN) halves its staff as losses climb - Stock Titan
ENGN 10-Q FilingsenGene Therapeutics Inc SEC 10-Q - Stock Titan
enGene Reports $32.5 Million Third-Quarter Net Loss and $266.3 Million Cash - Quiver Quantitative
enGene Therapeutics Inc. expected to post a loss of 43 cents a shareEarnings Preview - TradingView
EnGene to Spotlight Bladder Cancer Gene Therapy at Major Investor Conferences - TipRanks
enGene to Participate in Upcoming Investor Conferences - Yahoo Finance
Deep Track Capital Exits enGene Therapeutics (ENGN) Stake in Sec - GuruFocus
enGene Holdings (ENGN) Edges Higher: Gene Therapy Stock Holds Key Support at $1.64Retail Driven Moves - dars.gov.et
enGene Therapeutics Inc. Stock 12‑Month Price Target Cut to $3.43, Implies 102% Upside - TradingView
enGene (NASDAQ:ENGN) Raised to "Sell" at Wall Street Zen - MarketBeat
Perceptive Advisors (NASDAQ: ENGN) discloses 9.99% beneficial stake with warrant cap - Stock Titan
enGene Holdings (ENGN): Venrock investor group reports 0.0% stake and no voting power - Stock Titan
Deep Track exits enGene Therapeutics (ENGN) position, reports 0% ownership - Stock Titan
Raymond Debbane (ENGN) discloses 9.3% enGene stake via Invus and Avicenna - Stock Titan
enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market - MarketBeat
Blue Owl Capital Holdings (ENGN) discloses 0.76% warrant-based stake in enGene - Stock Titan
enGene Therapeutics Inc. (S0N0.F) analyst ratings, estimates and forecasts - uk.finance.yahoo.com
enGene highlights detalimogene NMIBC KOL insights and outlook - TipRanks
enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder CancerSlideshow (NASDAQ:ENGN) 2026-08-11 - Seeking Alpha
enGene Therapeutics Inc.Common Stock (ENGN) Stock Price, News, Quote & History - FinancialContent
enGene Holdings Inc (ENGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
enGene Therapeutics Inc. (S0N0.F) Latest Press Releases & Corporate News - Yahoo! Finance Canada
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026 - Business Wire
enGene Holdings Inc. (NASDAQ:ENGN) Given Consensus Rating of "Hold" by Analysts - MarketBeat
enGene Therapeutics Inc. Revenue Breakdown – BOATS:ENGNW - TradingView
enGene (NASDAQ:ENGN) Downgraded to "Strong Sell" Rating by Wall Street Zen - MarketBeat
enGene Therapeutics Inc. Revenue Breakdown – NASDAQ:ENGN - TradingView
Siren L.L.C. Has $35.77 Million Stake in enGene Holdings Inc. $ENGN - MarketBeat
Executive options at enGene Therapeutics (ENGN) vesting over 4 years - Stock Titan
enGene Therapeutics (NASDAQ: ENGN) outlines insider RSUs and options - Stock Titan
Engene Therapeutics Inc Stock (ENGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):